Analysis Tools
neoplasm
|
• tamoxifen-treatment halts cancer progression and lowers tumor burden with increased senescence of tumor cells compared to in control mice
|
|
Allele Symbol Allele Name Allele ID |
Tg(MMTV-Erbb2)NK1Mul transgene insertion NK1, William Muller MGI:3050871 |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
12 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen-treatment halts cancer progression and lowers tumor burden with increased senescence of tumor cells compared to in control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• female virgin mice develop mammary tumors by 54 weeks of age which is slightly but not significantly later than in mice carrying the transgene on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung occurs in some mice
|
|
• female virgin mice develop mammary tumors by 54 weeks of age which is slightly but not significantly later than in mice carrying the transgene on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung occurs in some mice
|
|
• female virgin mice develop mammary tumors by 54 weeks of age which is slightly but not significantly later than in mice carrying the transgene on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung occurs in some mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• female virgin mice develop mammary tumors by 45 weeks of age which is significantly earlier than occurs in mice carrying the transgene on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung occurs in some mice
|
|
• female virgin mice develop mammary tumors by 45 weeks of age which is significantly earlier than occurs in mice carrying the transgene on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung occurs in some mice
|
|
• female virgin mice develop mammary tumors by 45 weeks of age which is significantly earlier than occurs in mice carrying the transgene on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung occurs in some mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 10% of female virgin mice develop mammary tumors by 60 weeks of age which is a much lower incidence than occurs in mice carrying the transgene on a wild-type background
• tumor growth in mammary glands is significantly slower than is found in transgenic mice on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung is slightly enhanced in these mice
|
|
• 10% of female virgin mice develop mammary tumors by 60 weeks of age which is a much lower incidence than occurs in mice carrying the transgene on a wild-type background
• tumor growth in mammary glands is significantly slower than is found in transgenic mice on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung is slightly enhanced in these mice
|
|
• 10% of female virgin mice develop mammary tumors by 60 weeks of age which is a much lower incidence than occurs in mice carrying the transgene on a wild-type background
• tumor growth in mammary glands is significantly slower than is found in transgenic mice on a wild-type background
• intravascular metastasis of adenocarcinomas into the lung is slightly enhanced in these mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice display 50% tumor incidence at 105 weeks of age compared to 52 weeks of age in transgenic mice wild-type for Esr1
• increasing progesterone levels accelerates tumor development
|
 |
• rudimentary mammary gland that fails to develop beyond the prepubertal stage
• however, duct structure is not different from homozygous null mice not carrying the transgene
|
|
|
• rudimentary mammary gland that fails to develop beyond the prepubertal stage
• however, duct structure is not different from homozygous null mice not carrying the transgene
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 50% of mice develop tumors by about 45 weeks, same rate of occurrence as transgene alone
|
|
• 50% of mice develop tumors by about 45 weeks, same rate of occurrence as transgene alone
|
|
• 50% of mice develop tumors by about 45 weeks, same rate of occurrence as transgene alone
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• resistant to Erbb2-induced breast cancers
|
|
• resistant to Erbb2-induced breast cancers
|
|
• resistant to Erbb2-induced breast cancers
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop tumors at a latency of 32 weeks compared to 23 weeks in Tg(MMTV-Erbb2)NK1Mul transgenic mice
• mice do not develop hyperplastic nodules in mammary glands as do Tg(MMTV-Erbb2)NK1Mul transgenic mice
|
|
• fewer cells are in S-phase and proliferation is decreased compared to in Tg(MMTV-Erbb2)NK1Mul transgenic mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• all female virgin mice develop cancer tumors in the breast by 45 weeks of age
|
|
• all female virgin mice develop cancer tumors in the breast by 45 weeks of age
|
|
• all female virgin mice develop cancer tumors in the breast by 45 weeks of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• about 20% of mutants develop mammary tumors by the 25th week of age, and by the 30th week, tumor incidence increases to 83%
• high dose of flaxseed oil (with a an omega6:omega3 fatty acid ratio of about 1) results in some delay in the growth of mammary tumors, however low and mid doses with omega6:omega3 ratios of 7.7 and 3.1 enhance tumor development
• melatonin treatment delays the appearance of palpable tumors
• combination of both flaxseed oil and melatonin results in a slight delay of tumor development, similar that seen with melatonin only
|
|
|
• about 20% of mutants develop mammary tumors by the 25th week of age, and by the 30th week, tumor incidence increases to 83%
• high dose of flaxseed oil (with a an omega6:omega3 fatty acid ratio of about 1) results in some delay in the growth of mammary tumors, however low and mid doses with omega6:omega3 ratios of 7.7 and 3.1 enhance tumor development
• melatonin treatment delays the appearance of palpable tumors
• combination of both flaxseed oil and melatonin results in a slight delay of tumor development, similar that seen with melatonin only
|
|
|
• about 20% of mutants develop mammary tumors by the 25th week of age, and by the 30th week, tumor incidence increases to 83%
• high dose of flaxseed oil (with a an omega6:omega3 fatty acid ratio of about 1) results in some delay in the growth of mammary tumors, however low and mid doses with omega6:omega3 ratios of 7.7 and 3.1 enhance tumor development
• melatonin treatment delays the appearance of palpable tumors
• combination of both flaxseed oil and melatonin results in a slight delay of tumor development, similar that seen with melatonin only
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| breast cancer | DOID:1612 |
OMIM:114480 |
J:67457 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• Background Sensitivity: mice display 50% tumor incidence at 52 weeks of age compared to 25 weeks of age in mice on an FVB/N background
• mice ovariectomized at 18-20 days of age, but not those ovariectomized at 16-20 weeks of age, display a further delay in tumor onset (50% incidence at 62 weeks of age)
• breeding females accelerates tumor development (50% incidence at 32 weeks of age)
|
| N |
• unlike in previous reports, mammary gland ductal structure is not different from controls prior to the onset of tumor formation
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• female mice exhibit diffuse, polyclonal tumor masses
• tumor morphogenesis corresponds to transgene expression
• tumors are more sparsely distributed than in other lines of the transgene
|
|
• female mice exhibit diffuse, polyclonal tumor masses
• tumor morphogenesis corresponds to transgene expression
• tumors are more sparsely distributed than in other lines of the transgene
|
|
• female mice exhibit diffuse, polyclonal tumor masses
• tumor morphogenesis corresponds to transgene expression
• tumors are more sparsely distributed than in other lines of the transgene
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||